Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041720 | 0.79 | MIF (0.31) | MIFKDM4ELMNAGAAMAPT | |
| SCHEMBL3686592 | 0.63 | ALDH1A1 (0.37) | GAAMAPTKMT2APRKCA | |
| SCHEMBL5041707 | 0.63 | LDHA (0.33) | — | |
| Hydroquinone SCHEMBL6353777 | 0.59 | ADRB2 (0.46) | MIFADRB2ADRB1ADRB3KDM4E | |
| Hydroquinone SCHEMBL9547887 | 0.57 | ALDH1A1 (0.67) | MIFKDM4ELMNAGAAMAPT | |
| Hydroquinone SCHEMBL28100131 | 0.57 | ALDH1A1 (0.67) | MIFKDM4ELMNAGAAMAPT | |
| SCHEMBL6359655 | 0.56 | ADRB2 (0.43) | ADRB2ADRB1ADRB3KDM4ELMNA | |
| SCHEMBL126492 | 0.56 | ALDH1A1 (0.69) | KDM4ELMNAKMT2A | |
| SCHEMBL6352900 | 0.55 | ESR1 (0.44) | MIFADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL16244120 | 0.55 | ESR1 (0.36) | ADRB1ADRB3KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628974-A4 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) | BRISTOL MYERS SQUIBB CO (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7132432-B2 | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1628974-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004108086-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040254231-A1 | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254231-A1 | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, MMP3 | MIF 100/4885ADRB2 4791/4885ADRB1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.